# A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

> **NCT05201911** · PHASE1 · COMPLETED · sponsor: **Attralus, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Amyloidosis; Systemic

## Interventions

- **DRUG:** 124I-AT03

## Key facts

- **NCT ID:** NCT05201911
- **Lead sponsor:** Attralus, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201911, "A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05201911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*